# China NMPA Drug Inspection - Chongqing Knight Hospital - Heart-Nourishing and Brain-Boosting Mixture

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/chongqing-knight-hospital/708a9f20-f331-4097-81a4-25a6983b0450/
Source feed: China

> China NMPA drug inspection for Chongqing Knight Hospital published October 22, 2020. Drug: Heart-Nourishing and Brain-Boosting Mixture. The Chongqing Municipal Drug Administration's 2018 Issue No. 2 Drug Quality Announcement detailed findings of substandar

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Chongqing Municipal Drug Administration's Drug Quality Bulletin, Issue 2, 2018
- Company Name: Chongqing Knight Hospital
- Publication Date: 2020-10-22
- Drug Name: Heart-Nourishing and Brain-Boosting Mixture
- Inspection Finding: The filling amount does not meet the requirements.
- Action Taken: Seizure, impounding, suspension of sales, product recall, filing of cases for investigation, and urging the investigation of causes and the implementation of corrective measures.
- Summary: The Chongqing Municipal Drug Administration's 2018 Issue No. 2 Drug Quality Announcement detailed findings of substandard pharmaceutical products from two entities: Chongqing Knight Hospital (also referred to as Chongqing Qishi Hospital) and Chongqing Kangjia Pharmaceutical Co., Ltd. Published on December 29, 2018, the report identified three specific batches of drugs that failed to meet national quality standards following inspections by local food and drug testing institutes. The violations involved Calamine Lotion and Yixin Bunao Mixture from Chongqing Knight Hospital, which failed borax content and quantity determination tests, respectively. Additionally, a batch of Lotus Seed Heart produced by Chongqing Kangjia Pharmaceutical was found non-compliant regarding its content determination. In response to these findings, the Jiangbei and Hechuan District regulatory branches executed immediate enforcement actions under China's drug administration laws. These measures included sealing and seizing existing stock, suspending sales, and initiating product recalls to protect public health. The regulatory framework requires the manufacturers to conduct thorough internal investigations to identify the root causes of these quality failures. Furthermore, the companies must formulate and implement formal rectification measures to eliminate potential safety risks and ensure future compliance with pharmaceutical standards.

Company: https://www.globalkeysolutions.net/companies/chongqing-knight-hospital/113c7216-f67d-4511-867b-a1f8df088979/